Teva Pharm Indus Ltd earned $1.21 per diluted share in fiscal year 2025. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to $0.60 per diluted share. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Teva Pharm Indus Ltd has filed alongside them.
FY2025 annual
EPS (Diluted)$1.21
YoYn/m
5Y CAGRn/m
Source SEC Filings (10-K/10-Q)Latest period Q2 FY2026, ended Jun 30, 2026ReportedCurrency USD
Annual figures, oldest first. Point at a bar to read its period.
TEVJF EPS (Diluted) by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
Teva Pharm Indus Ltd earned $1.21 per diluted share in fiscal year 2025.
Teva Pharm Indus Ltd (TEVJF) reported a loss of $1.45 per diluted share in fiscal year 2024 and $1.21 per diluted share in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.
Teva Pharm Indus Ltd (TEVJF) reported $0.60 per diluted share over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
Across the 15 fiscal years this page covers, Teva Pharm Indus Ltd (TEVJF) diluted earnings per share went from $3.09 in fiscal year 2011 to $1.21 in fiscal year 2025.
Teva Pharm Indus Ltd (TEVJF) reported -$0.49 in diluted earnings per share in Q2 2026. This represents a decrease of 304.2% from the same quarter a year earlier.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Teva Pharm Indus Ltd (TEVJF) reported on that line in every period on record.
